Management of Pregnancy with ABO Incompatibility
9/1/2011 - Michael T. Mennuti, MD
Editor: David Chelmow, MD
ABO incompatibility is the most common maternal-fetal blood group incompatibility and the most common cause of hemolytic disease of the newborn (HDN). ABO incompatibility is more often seen in newborns who have type A blood because of the higher frequency of type A compared to type B in most populations. It occurs more commonly in individuals of African or Latin American ethnicity. ABO incompatibility in the newborn generally presents as neonatal jaundice due to a Coombs positive hemolytic anemia and occurs in 0.5-1% of newborns. In contrast to the severe intrauterine or neonatal hemolytic anemia associated with Rh sensitization, clinically important neonatal anemia due to ABO incompatibility occurs infrequently. The major clinical issue with HDN due to ABO incompatibility is jaundice.
Several reasons have been proposed to account for lack of intrauterine hemolysis due to ABO incompatibility. These include less well developed A and B antigens on fetal red blood cells to stimulate maternal antibody production, and the ubiquitous distribution of A and B antigens in other tissues resulting in fewer antibodies that cross the placenta to bind to antigens on fetal red cells. The most important reason that ABO incompatibility does not cause hydrops fetalis is that naturally occurring anti-A and anti-B antibodies are IgM and do not cross the placenta.
It is estimated that <1% of type-O mothers have clinically significant anti-A or anti-B antibody which is IgG. ABO incompatibility with transplacental transfer of IgG anti-A antibody, or more commonly, anti-B antibody has rarely been reported in association with intrauterine hemolysis leading to hydrops fetalis. It should be noted that other causes of nonimmune hydrops fetalis have not been systematically excluded in these case reports. The most likely explanation for these rare cases is that exposure to antigens similar to the A or B antigen may occur from sources other than the fetus and stimulates IgG production in the mother. For example, an antigen similar to the B antigen is found in E.coli, and exposure to this organism may stimulate production of IgG anti-B antibody in type O individuals.
In contrast to Rh incompatibility, which tends to become more severe with each subsequent Rh positive pregnancy, ABO incompatibility does not demonstrate any consistent pattern. Thus, the patient’s first offspring may have clinically important hemolytic disease of the newborn due to ABO incompatibility, while subsequent newborns may be unaffected or very mildly affected. Because of the rarity of severe intrauterine hemolysis due to ABO incompatibility, assessment for intrauterine fetal anemia is not recommended based on the mother having type O blood. Measurement of IgG anti-A and anti-B antibody may be considered part of the evaluation of unexplained signs of fetal anemia such as ascites or hydrops when the mother is type O. Collecting a cord blood sample at birth for blood type and direct antibody testing should be considered when the mother is type O and a previous child had hemolytic disease of the newborn due to ABO incompatibility.
American College of Obstetricians and Gynecologists (ACOG), ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. Obstet Gynecol. 2018 Mar;131(3):e82-e90. doi: 10.1097/AOG.0000000000002528.
Initial Approval September 2011; Reviewed June 2015 & January 2017; Revised May 2018
********** Notice Regarding Use ************
The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright 2018 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved. No re-print, duplication or posting allowed without prior written consent.Back to Search Results